RCT | Two-year effects of Semaglutide in adults with overweight or obesity.

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial – Nature Medicine

Commentary: STEP 5: Sustained semaglutide treatment maintains weight loss – medwire News

Related:

RCT: Effect of continued weekly subcutaneous Semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity

RCT: High dose once a week Semaglutide (2.4 mg) in adults with overweight or obesity, and type 2 diabetes

RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity

RCT: Once-weekly, high-dose semaglutide is effective for improving overweight or obesity among non-diabetic adults

Commentary on Twitter

Results from the STEP 5, testing #semaglutide as an adjuct to behavioral interventions in adults with #overweight or #obesity, demonstrate sustained #weightloss over a period of 104 weeks. @ProfBatterhamMD @seanwharton @DrGeorgiaRigas https://t.co/0mBtzhCYID

— Nature Medicine (@NatureMedicine) October 11, 2022